Antineoplastic Agents/pharmacology; Drug Inverse Agonism; Receptor, Cannabinoid, CB1/agonists; Receptor, Cannabinoid, CB2/agonists; Selective Estrogen Receptor Modulators/pharmacology; Tamoxifen/analogs & derivatives; Tamoxifen/pharmacology; Animals; Antineoplastic Agents/chemistry; CHO Cells; Cell Membrane/chemistry; Cricetulus; Humans; Mice; Protein Binding; Receptor, Cannabinoid, CB1/chemistry; Receptor, Cannabinoid, CB2/chemistry; Selective Estrogen Receptor Modulators/chemistry; Tamoxifen/chemistry

4OH-Tam; 4OH-Tamoxifen; 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol; AC; Antagonist; CB1R; CB2R; CHO; CP-55,940; Cannabinoid receptors; Cannabinoids; Chinese hamster ovary; DMEM; Drug action; Drug discovery; Dulbecco's modification of Eagle's medium; ER; G-protein coupled receptor; G-protein coupled receptors; GPCR; IBMX; Inverse agonist; SERM; Tam; Tamoxifen; WIN-55,212-2; [(35)S]GTPγS; [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone; adenylyl cyclase; cannabinoid receptor type 1; cannabinoid receptor type 2; estrogen receptor; guanosine 5'-O-(3-[(35)S]thio)triphosphate; hCB2; hMOR; human CB2 receptors; human mu-opioid receptors; isobutyl-methyl-xanthine; selective estrogen receptor modulator